G12C KRAS inhibitors Archives

Mirati and Sanofi Unite on Trial for KRAS Inhibitor

Agreements, Business, Clinical Trials, Colorectal Cancer, Deals, G12C KRAS inhibitors, KRAS G12C Mutations, Non-Small Cell Lung Cancer, R&D, Sanofi, SHP2 inhibitors

Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.

Mirati Grabs Breakthrough Therapy Designation for KRAS inhibitor

Biomarkers, Breakthrough Therapy Designation, FDA, G12C KRAS inhibitors, Mutations, Non-Small Cell Lung Cancer (NSCLC), Proteins, Studies

The U.S. Food and Drug Administration made the decision to grant Breakthrough Therapy Designation to Mirati Therapeutics’ adagrasib for the potential treatment of non-small cell lung cancer (NSCLC) in patients harboring the KRASG12C mutation after systemic therapy.

Researchers Develop New Class of Lung Cancer Drugs

Chemotherapy, Clinical Trials, Drug-resistant tumors, Francis Crick Institute, G12C KRAS inhibitors, IGF1R Pathway, KRAS gene, KRAS Mutations, Lung adenocarcinoma, Lung Cancer, mTOR Pathway, Mutations, R&D, Researchers, Science Translational Medicine, The Institute of Cancer Research (ICR)

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.